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Excess α-synuclein compromises 
phagocytosis in iPSC-derived 
macrophages
Walther Haenseler1, Federico Zambon2,3, Heyne Lee1, Jane Vowles1,3, Federica Rinaldi1, 
Galbha Duggal4, Henry Houlden5, Katrina Gwinn  6, Selina Wray5, Kelvin C. Luk  7,  
Richard Wade-Martins2,3, William S. James1 & Sally A. Cowley  1,3
To examine the pathogenic role of α-synuclein (αS) in Parkinson’s Disease, we have generated induced 
Pluripotent Stem Cell lines from early onset Parkinson’s Disease patients with SNCA A53T and SNCA 
Triplication mutations, and in this study have differentiated them to PSC-macrophages (pMac), which 
recapitulate many features of their brain-resident cousins, microglia. We show that SNCA Triplication 
pMac, but not A53T pMac, have significantly increased intracellular αS versus controls and release 
significantly more αS to the medium. SNCA Triplication pMac, but not A53T pMac, show significantly 
reduced phagocytosis capability and this can be phenocopied by adding monomeric αS to the cell 
culture medium of control pMac. Fibrillar αS is taken up by pMac by actin-rearrangement-dependent 
pathways, and monomeric αS by actin-independent pathways. Finally, pMac degrade αS and this 
can be arrested by blocking lysosomal and proteasomal pathways. Together, these results show 
that macrophages are capable of clearing αS, but that high levels of exogenous or endogenous αS 
compromise this ability, likely a vicious cycle scenario faced by microglia in Parkinson’s disease.
α-synuclein (αS) is a small, 14.5 kD, usually monomeric protein, that is highly expressed in neurons, where it 
can make up to 1 % of cytosolic protein, localising notably to presynaptic termini1. In Parkinson’s Disease (PD) 
it forms oligomers and fibrils, a major component of Lewy bodies and a hallmark of PD2. Overexpression or 
mutations in the SNCA gene, which encodes αS, can cause relatively early onset familial PD3–5. PD is character-
ised by loss of dopaminergic neurons in the Substantia nigra, therefore most studies focus on cell-autonomous 
pathological processes within dopaminergic neurons. However, non-neuronal cell processes likely also play a role 
in the progression of PD, with astrocytes and microglia being implicated through their expression of several key 
PD-related genes, including GBA, LRRK2 and SNCA6.
Microglia are brain-resident macrophages, and are professional phagocytes, responsible for the homeostatic 
clearance of cellular debris, dying cells, incompetent synapses and aggregation-prone proteins. However, they 
can be provoked into a damaging, reactive state by inflammatory stimuli, triggering cytokine release (especially 
TNFα), potentially exacerbating neuronal damage and creating a vicious cycle of cytokine production and neu-
ronal destruction (reviewed by refs 7 and 8). It is clearly important to examine the role of macrophages/micro-
glia in clearing αS, and conversely, to understand whether the function of macrophages/microglia is affected 
by the presence of excess or mutant forms of the protein, as found in PD. Here, we examine this for the first 
time using human induced Pluripotent Stem Cells (iPSC) generated from PD patients with SNCA A53T muta-
tion or the extremely rare SNCA Triplication. We differentiate the iPSC to adherent macrophages (pMac) via 
non-adherent macrophage precursors (pMacpre), following our previously published protocol9. These pMac rep-
resent yolk-sac-derived, tissue-resident macrophages10, 11 and therefore share the same ontogeny as microglia, 
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which migrate into the fetal brain from the yolk-sac before the formation of the blood-brain barrier. Moreover, 
they can be skewed towards a microglial phenotype by co-culture with iPSC-neurons12. They are, therefore, a 
better model for microglia-related research questions than patient blood-derived monocytes, which derive from 
adult bone-marrow-hematopoiesis. pMac also overcome the limited availability of patient blood samples, and the 
complicating effects of medication and co-morbidities on immune cellular phenotypes.
We observe increased intracellular and extracellular αS in Triplication pMac, but not in A53T pMac. We 
report decreased phagocytosis by SNCA Triplication pMac, but not A53T pMac, and this decrease is phenocopied 
in healthy control pMac by addition of monomeric αS. pMac take up monomeric and fibrillar αS, degrading αS 
via lysosomal and proteasomal pathways. Macrophages therefore clear αS, but are easily intoxicated by higher 
than physiologically normal levels.
Results
SNCA Triplication, but not SNCA A53T mutation, causes elevated intracellular and extracel-
lular αS protein levels in pMacpre and pMac. Multiple iPSC lines generated from 3 A53T patients, 1 
Triplication patient and 4 normal control donors, all differentiated successfully to pMacpre and pMac (Table 1, 
Fig. 1A, Table S1, Figs S1–3). SNCA gene expression levels in pMac from control donors was not significantly dif-
ferent to levels in blood-derived monocytes and macrophages (Fig. S4). In controls and A53T pMac, αS positive 
puncta were found distributed throughout the cytosol by confocal microscopy, with a proportion of the signal 
apparently in the nucleus, as described previously for neurons13. Triplication pMac had many more αS puncta 
(Fig. 1B). Relative quantification of intracellular αS levels by flow cytometry, showed no significant difference in 
A53T pMacpre and pMac versus controls, but Triplication pMacpre and pMac had a significant (3-fold) increase 
in intracellular αS (Fig. 1C–E), and were significantly more granular as assessed by flow cytometry, whilst their 
size was not significantly different from controls (Figure S3B,C).
αS levels in 7-day tissue culture medium were not significantly different for A53T pMac (1001 pg/ml ± 261; 
mean ± SEM, n = 13) versus control (506 pg/ml ± 81; n = 12), but were significantly higher with Triplication 
(3473 pg/ml ± 572; n = 7) (Fig. 1F). αS levels in XVIVO15 medium alone were at the lower detection limit 
of the assay (58 pg/ml ± 1.8; n = 4). These αS levels secreted by pMac were comparable to those secreted by 
iPSC-dopaminergic neuronal cultures (previously published14, measured using the same assay platform), which 
ranged from ~100–400 pg/ml in 2-day supernatant from controls and ~200–800 pg/ml for lines from patients 
harbouring N370S mutations in the Parkinson’s disease-associated gene for glucocerebrosidase, GBA.
Cytokines in supernatants from unstimulated pMac were not significantly different from controls for 
Triplication or A53T for the majority of cytokines measured, including for the key proinflammatory cytokine 
TNFα (34-plex, Fig. 2 and Table S2). However, the chemokine CXCL1 (GRO-α), and the proinflammatory 
cytokines IL-18 and IL-22 were significantly constitutively upregulated in Triplication pMac versus controls (3, 
2 and 1.5-fold respectively), suggesting a modest, specific dysregulation of cytokine production in macrophages 
overexpressing SNCA.
Together, these results show that pMac express αS and release it to the medium, and that this is significantly 
increased in Triplication mutants, suggesting that their brain resident cousins, microglia, may contribute to accu-
mulation of αS in the brain and possibly to the spreading of αS species.
Excess αS levels, but not A53T mutation, reduces phagocytosis in pMac. To investigate 
whether phagocytosis, endocytosis or pinocytosis pathways are perturbed in αS mutant pMac, particle uptake 
ID of iPSC 
clone, this 
study
STEMBANCC/OPDC ID of 
iPSC clone Diagnosis SNCA Genotype Sex
Age of 
Biopsy 
(years)
Reprogramming 
method
Fibroblast 
characterised 
(original ID)
iPSC clone 
characterised GEO
CTL1 SFC180–01–01 healthy control WT/WT female 60 Cytotune1 this study GSE89886
CTL2.1 SFC840-03-03/AH017-13
healthy control WT/WT female 67 Cytotune1 14
14 GSE53426
CTL2.2 SFC840-03-05 this study GSE89886
CTL2.3 SFC840-03-06 this study GSE89886
CTL3 SFC841-03-01 healthy control WT/WT male 36 Cytotune1 42 42 GSE64582
CTL4 SFC856-03-04 healthy control WT/WT female 78 Cytotune1 this study GSE89886
CTL5 AH016-3 healthy control WT/WT male 80 rv SO³KMN 43 43 GSE77664
CTL6 SFC854-03-02 healthy control WT/WT male 72 Cytotune1 This study GSE89886
A53T1.1 SFC828-03-04
PD A53T/WT female 51 Cytotune1 A53T_360
this study GSE89886
A53T1.2 SFC828-03-06 this study GSE89886
A53T2.1 SFC829-03-04
PD A53T/WT male 46 Cytotune1 A53T_065
this study GSE89886
A53T2.2 SFC829-03-06 this study GSE89886
A53T3.1 SFC830-04-08
PD A53T/WT male 51 Cytotune1 A53T_660
this study GSE89886
A53T3.2 SFC830-04-09 this study GSE89886
TPL1.1 SFC831-03-01
PD Triplication/WT female 55 Cytotune1 44
this study GSE89886
TPL1.2 SFC831-03-03 this study GSE89886
TPL1.3 SFC831-03-05 this study  GSE89886
Table 1. iPSC lines used in this study.
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by macrophages was assayed with Alexafluor488-conjugated killed yeast particles (zymosan)9, 10 kD dextran 
or transferrin15, respectively. A53T pMac had a very modest increase in zymosan uptake (118% ± 7; n = 24). 
Triplication lines, in contrast, showed a highly significant reduction in zymosan uptake (51% ± 4; n = 17) versus 
controls (n = 33) (Fig. 3A–C). Meanwhile, only very modest or no differences were detected in dextran and trans-
ferrin uptake in SNCA mutant lines versus controls (Figure S5A–C). Therefore, excess endogenous αS compro-
mises phagocytic but not endocytic or pinocytic ability in pMac.
To explore whether increased levels of endogenously expressed αS was responsible for this phagocytic defect 
phenotype, we applied exogenous monomeric αS to the pMac. Phagocytosis of zymosan negatively correlated 
with monomeric αS dose and exposure time–2 µg/ml for 2 hrs showed an effect (Fig. 3D), and 10 µg/ml or 50 µg/
ml for 24 hrs gave a highly significant reduction (Fig. 3E). Therefore, excess exogenous αS has the same detrimen-
tal effect as excess endogenously-derived αS on phagocytic ability of pMac, confirming that the effect seen with 
the Triplication lines is not due to another genetic defect in these lines.
Figure 1. pMacpre and pMac expression of αS. (A) iPSC differentiation to macrophages (scale bar = 200 
µm). (B) Intracellular staining for αS in pMac, representative z projected confocal images (scale bar = 20 
µm). (C,D,E) Intracellular levels of αS by flow cytometry: (C) Representative αS FACs plots of pMacpre; (D) 
pMacpre αS levels (geometric mean fluorescence intensity, MFI); (E) pMac αS levels. (F) αS levels in 7-day 
supernatant from pMac. Values normalized to WT mean for each independent experiment. Also see Figs S1–3 
Statistical analyses, one way ANOVA with Dunnett’s multiple comparisons test.
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pMac take up fibrillar and monomeric αS. We next examined whether and how αS is taken up by con-
trol pMac. Phagocytic uptake of fluorescently labelled αS fibrils was readily observable by time-lapse microscopy 
(Fig. 4A, Video S1). Adding exogenous monomeric αS increased intracellular levels of αS in a dose-dependent 
manner (Fig. 4B). 10 µg/ml for 2 hrs gave levels similar to SNCA Triplication, and thus, was chosen for fur-
ther analyses. Uptake of monomeric αS was not affected by blocking actin polymerisation with cytochalasin D 
(Fig. 4C), implying uptake by mechanisms that are actin-rearrangement-independent, so not phagocytosis or 
macropinocytosis or actin-dependent endocytosis16. Further, uptake was not inhibited by Dynasore (Figure S5G), 
so not dynamin-dependent endocytosis, so uptake of monomeric αS could include direct traverse across the 
plasma membrane17. In contrast, uptake of fibrillar αS was significantly reduced by blocking actin polymerisa-
tion, so likely to employ phagocytosis (or possibly macropinocytosis or actin-dependent endocytosis for smaller 
aggregates) (Fig. 4D,E).
Lipopolysaccharide (LPS) triggered strong TNFα release in pMac (3082 ± 34; n = 3), but monomeric αS and 
fibrillar αS did not (29 pg/ml ± 3; n = 3; 38 pg/ml ± 14 respectively) (Fig. 4F). LPS stimulation of SNCA mutant 
pMac triggered the same level of TNFα release as control pMac (Supplementary Figure 5D).
Figure 2. Cytokine and chemokine release by healthy control and SNCA mutant pMacs. Supernatants from 
pMac were assayed with Cytokine & Chemokine 34-Plex Human ProcartaPlex. Selected results are shown here, 
further cytokine results are shown in Table S2. Statistical analyses one way ANOVA with Dunnett’s multiple 
comparisons test.
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Together, this shows that pMac readily take up monomeric αS by actin-rearrangement-independent path-
ways, and fibrillar αS by actin-dependent pathways, and are not provoked under these baseline conditions into 
releasing TNFα in response to αS, whether exogenous, endogenous, monomeric, fibrillar or mutant. This also 
shows that the phagocytic defect shown in the presence of excess αS is not the result of autocrine or paracrine 
TNFα signalling.
pMac degrade αS by both lysosomal and proteasomal pathways. To investigate whether pMac 
were capable of degrading exogenous αS, pMac were incubated with monomeric αS, then collected, washed and 
replated onto fresh plates (to completely remove any remaining extracellular αS, which readily sticks to plastic). 
Endogenous αS staining localised to small puncta, mainly in the nucleus, with a few puncta in the cytosol, and 
little co-localisation of αS with the lysosome marker LAMP1 (Figs 1A, 5A). After 2 hrs of exposure to monomeric 
αS, larger αS puncta were visible in the cytosol of a subset of cells, partly co-localising with LAMP1 (Fig. 5B), as 
well as accumulating near the cell surface. After washing, and replating for 4 hrs, αS no longer localised to the cell 
surface but showed increased co-localisation with LAMP1 (Fig. 5C).
The timecourse of depletion of monomeric αS from pMac was assessed by flow cytometry. αS levels in the 
pMac after αS-challenge and replating were ~4-fold higher than endogenous levels, indicating substantial uptake 
of αS, but by 22 hrs levels had dropped back to near-endogenous levels (Fig. 5D), implying that they had either 
expelled or degraded the excess.
To assess expulsion of αS by pMac, extracellular αS levels in supernatants from the above experiment were 
measured (Fig. 5E). 30 mins after replating, extracellular αS levels were similar to 4-day supernatant from 
Figure 3. High levels of αS reduce phagocytosis in pMac. Phagocytosis was measured by uptake of fluorescent 
zymosan by pMac. (A) Z-projection of confocal images (scale bar = 20 µm). (B) representative FACS plots of 
zymosan uptake (black line, untreated with cytochalasin D; gray, cytochalasin D-treated). (C) Quantification 
of (B) (3 independent experiments). (D) Incubation with monomeric αS for different lengths of time, then 
challenge with zymosan (one line). (E) Incubation with different concentrations of monomeric αS (24 hr), then 
challenge with zymosan. Values normalized to untreated mean for each of 3 independent experiments (C,E). 
Statistical analyses, one way ANOVA with Dunnett’s multiple comparisons test. Also see Figure S4A–C.
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untreated pMac (838 pg/ml ± 106; n = 3, and 882 pg/ml ± 188; n = 3). By 22h, levels of secreted αS nearly dou-
bled (1407 pg/ml ± 313; n = 3), but were still about 7000 fold below input, and were below the levels measured in 
SNCA Triplication pMac supernatants.
To establish whether αS taken up by pMac is degraded within the cells, and if so by what mechanism, degrada-
tion pathway-specific drugs were added into the assay at the point of replating. Leupeptin (broad-spectrum pro-
tease inhibitor), MG132 (26S proteasome inhibitor) and Bafilomycin A1 (prevents vesicle acidification, thereby 
inhibiting lysosomal function) were each able to inhibit degradation of αS, as measured after 8 hrs, by 2–3-fold 
(Fig. 5F). Applying these pathway inhibitors to pMac not treated with exogenous αS did not significantly alter 
endogenous αS levels (Fig. 5G).
Together, these results show that endogenous αS is relatively stable over the timeframe of these assays, and 
that pMac can expel exogenously acquired αS and also degrade it by both lysosomal and proteasomal pathways.
Discussion
This study demonstrates that αS can compromise the ability of professional phagocytes to conduct their normal 
homeostatic phagocytic functions, which includes clearance of αS, and likely contributes to the build-up of αS in 
PD patients. Our results are the first to use iPSC-derived macrophages from PD patients harbouring SNCA muta-
tions and controls to study αS, enabling expression at the correct gene dosage in this highly relevant, authentic 
human cell type.
Figure 4. pMac take up fibrillar and monomeric αS. (A) 10 µg/ml Oregon Green 488-labelled fibrillar αS 
was added to pMac (imaged every 5 mins, 18 hrs). Frames capture one selected phagocytosis event (scale 
bar = 50 µm). (B) Intracellular αS levels following incubation with monomeric αS (FACs), normalized 
to mean endogenous αS levels in untreated pMac. (C) pMac incubated with monomeric αS, with or 
without Cytocholasin D (FACs as in (B)). (D) pMac incubated with fluorescent αS fibrils, with and without 
Cytocholasin D (FACs), MFI fluorescent αS divided by MFI medium only. (E) as per (D) but lower dose and 
shorter time. (F) TNFα levels in pMac supernatants measured 24 hrs after monomeric or fibrillar αS or LPS. 
Statistical analyses: (C,D,E) two-tailed t-test; (B,F) one way ANOVA with Dunnett’s multiple comparisons test. 
Also see Figure S4D–F.
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Figure 5. pMac degrade exogenous αS. (A) Immunocytochemistry of pMac: αS (green); lysosomal marker 
LAMP1 (red); nuclei (DAPI, blue; scale bar = 20 µm), region within white square is magnified below. (B) As (A) 
but pMac treated for 2 hrs with 10 µg/ml αS. (C) As (B), but pMac then washed and replated (4 hrs). (D) pMac 
incubated for 2 hrs with 10 µg/ml monomeric αS, washed and replated for the indicated number of hrs before 
assaying for intracellular αS by FACs; MFI relative to endogenous αS in untreated pMac. (E) Release of αS to 
supernatant of same experiment as (D). (F) As (D), with the addition of degradation pathway-specific drugs 
upon replating pMac after αS exposure and incubation for 8 hrs. (G) Pathway-specific drugs were added to cells 
(without exogenous αS exposure) for 2 and 8 hrs and assayed for intracellular accumulation of endogenous αS 
by FACs. (F,G) 1 line, 3 independent differentiations. Statistical analyses: (E) two-tailed t-test; (D,F,G) one way 
ANOVA with Dunnett’s multiple comparisons test.
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SNCA Triplication is extremely rare4. The availability of iPSC from these patients has so far been limited to 
samples from two individuals, a 48 year old male18–20 and a 55 year old female21, 22, the latter being the same indi-
vidual from which we have derived the iPSC used in this study, and which are the first SNCA Triplication iPSC 
to be derived with non-integrating reprogramming vectors. Because of this rarity, we were not able to extend our 
results to iPSC-macrophages from additional SNCA Triplication patients. However, the observed phenotype was 
reproduced across all three clones from this patient. Moreover, we have shown for the first time that exogenous 
αS phenocopies the phagocytic defect displayed by SNCA Triplication pMac, indicating that excess αS affects 
phagocytosis, whether endogenous or exogenously derived.
Our results showing the negative impact of excess endogenous αS on phagocytosis concur with and extend the 
results of others using mice over-expressing human SNCA from a bacterial artificial chromosome23. That system 
relies on expression of human αS on a mouse background, and αS levels are not as precisely comparable to the 
SNCA Triplication patient as in our pMac system. Our results also concur with and extend results using SNCA 
triplication patient monocytes23. pMac, being entirely in vitro, are not exposed to any confounding or compound-
ing in vivo or ex vivo factors, such as chronic inflammation, so results obtained with pMac likely reflect a primary 
defect, rather than a secondary effect. Patient monocytes may be compromised by the effects of PD drug regimens 
and the patients’ physiological status, whereas pMac have never been exposed to patient cytokines, drugs, etc. 
Consistent with this, pMac do not produce TNFα in response to monomeric or fibrillar αS or SNCA mutation, 
presumably because they have not been exposed to any priming cytokines, whereas increased TNFα shown to be 
released from mouse microglia overexpressing SNCA is likely due to chronic activation in the in vivo system23, 24.
In our system A53T SNCA did not lead to a significant increase in αS levels (Fig. 1B–E), and did not 
affect phagocytosis (Fig. 2A–C), in contrast to the increased αS and decreased phagocytosis seen with SNCA 
Triplication. This was perhaps surprising, given that in neurons A53T is associated with accumulation of αS, but 
our results suggest that pMac, which are professional clearers of unwanted material, are better able to process 
mutant, misfolded A53T αS than neurons and do not accumulate it so readily.
αS uptake by other cell types has been described previously, including free passage through the plasma mem-
brane17, micropinocytosis25 and dynamin-dependent endocytosis26. Our results show for the first time that actin 
dynamics are involved in the uptake of fibrillar but not monomeric forms of αS in pMac, and time-lapse video of 
fibrillary uptake supports this. In Alzheimer’s Disease, microglia have been shown to congregate around amyloid 
beta plaques, yet are not able to phagocytose the plaques and instead become chronically activated27. We have 
previously shown that dopaminergic neurons harbouring PD-associated GBA mutations secrete increased levels 
of αS versus controls14. We postulate that macrophages and microglia take up αS as part of their homeostatic, 
non-inflammatory portfolio, but are similarly rendered less phagocytically competent by the locally very high 
levels of αS found in PD brains.
We explored whether pMac degrade and/or expel αS, and by what mechanisms, because if they expel sub-
stantial amounts, their microglial cousins could be potential contributors to the spread of αS in the brain. 
Microtubule-associated protein Tau, which forms tangles in Alzheimer’s Disease, is capable of being spread by 
release from murine microglia, and subsequent uptake by nearby neurons28. We found that pMac expelled αS 
both constitutively and following uptake, but lysosomal and proteasomal degradation of αS was also evident in 
pMac. In other cell types, αS has been shown to be ubiquitinated by Nedd4 before degradation by these routes29, 30. 
Since pMac, and by extension microglia, are capable of uptake, excretion and degradation of αS, manipulating 
the balance could be therapeutically useful. The use of anti-αS antibodies to promote αS uptake by microglia 
has already been investigated in mice31, 32, and humanised versions are starting to be trialled in PD patients. The 
pMac used here, as close cousins of microglia, offer a simple monoculture system to investigate the role of genes 
involved in neurodegeneration in the myeloid lineage. pMicroglia, developed from pMac recently by co-culture of 
pMac with iPSC-neurons by ourselves12 and by others along broadly similar routes33–36, offer an even more phys-
iologically relevant in vitro system and will be used to extend the observations made here in pMac. These models 
will enable us to understand and be able to fine-tune the balance between successful phagocytosis/destruction of 
opsonised αS by microglia, and destructive microglial over-activation and/or propagation of αS species.
Methods
Reagents were from ThermoFisher (Invitrogen) unless stated otherwise.
Reprogramming of patient fibroblasts to iPSC and differentiation to macrophages. As previ-
ously described9, 14, see Supplemental Information for methodological details.
All lines were derived from dermal fibroblasts from healthy donors or Parkinson’s disease patients, through 
StemBANCC (SF180, SF828, SF829, SF830, SF831), or the Oxford Parkinson’s Disease Centre (SF840, SF841, 
SF856, SF854, AH016): participants were recruited to this study having given signed informed consent, which 
included derivation of hiPSC lines from skin biopsies (Ethics Committee that specifically approved this part of the 
study: for control donors, National Health Service, Health Research Authority, NRES Committee South Central, 
Berkshire, UK, REC 10/H0505/71, and for SNCA patients REC 07/H0720/161); all experiments were performed 
in accordance with UK guidelines and regulations and as set out in the REC.
Determination of αS levels. pMacpre/pMac were fixed (4% PFA, 10 mins), washed (PBS), blocked/
permeabilized (flow cytometry buffer: PBS, 10 µg/mL human IgG [Sigma], 1% FCS [Hyclone], 0.01% sodium 
azide, 0.1% Saponin [Sigma], 30 mins), incubated with rabbit anti-αS antibody (MJFR1, Abcam) or rabbit IgG1 
(ab27478, Abcam) (1:250, 45 mins), washed x3 (flow cytometry buffer), incubated with donkey anti-rabbit 
IgG-Alexa647 (1:500), washed/resuspended (PBS) and assayed by flow cytometer (Calibur, BD) to obtain intra-
cellular αS levels. To compare results of replicate experiments carried out on different occasions, data was nor-
malized to the mean of healthy control lines of the corresponding experiment.
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7 day supernatant from pMac cultures was centrifuged (5 mins, 400 g) to remove cell debris, transferred to 
a new tube and stored at −80 °C. Supernatants were applied undiluted to a human αS detection kit (MesoScale 
Discovery, MSD).
Particle uptake. Uptake of dead yeast particles (zymosan) was assayed as described previously for pMac9, 37. 
Briefly, fluorescent zymosan particles were applied (2 particles/cell, 30 mins, 37 °C) in pMac differentiation 
medium (as a negative control for zymosan uptake, pMac were pre-treated (one hr) with 10 µM Cytochalasin D 
to inhibit actin polymerisation), or fluorescent dextran (D-22910) or fluorescent transferrin were applied at 50 
µg/ml, fluorescence of all extracellular particles blocked (0.025% Trypan blue [Sigma] in PBS), washed (PBS), 
released (TrypLE Express, 10 mins), collected gently with a cell scraper, fixed (4% PFA) and analysed by flow 
cytometer (Calibur, BD).
Recombinant αS. Recombinant human monomeric was purified as described previously38, 39. Endotoxin 
in αS preparations was removed using high capacity endotoxin spin columns (Pierce 88276) prior to labelling 
and/or aggregation into fibrils. A limulus amebocyte lysate (LAL) chromogenic kit (Pierce 88282) was used to 
measure endotoxin levels before and after treatment. Preparations containing endotoxin levels were >1 EU per 
mg of αS were used in experiments at a final dilution ≤10 µg/ml (i.e., ≤0.01 EU/ml). Monomeric αS was labeled 
with Oregon Green 488 succinimidyl-ester (Invitrogen) as per manufacturer’s instructions. Assembled fibrils 
contained a molar ratio of ≤1:10 (dye:protein). For αS uptake and degradation experiments, pMac were differ-
entiated in ultra-low attachment surface plates (Corning) to prevent αS attachment, and to allow resuspension 
of pMac without the use of a cell scraper. Before and during αS stimulation pMac were treated with Cytochalasin 
D (Sigma, 10 µM, to inhibit actin polymerisation) or Dynasore (Cayman Chemical, 80 µM, inhibits dynamin). 
After αS incubation, cells were lifted by pipetting, washed 3x with PBS and either used directly for determination 
of αS levels or replated in fresh medium to assay αS degradation. When replating, the following drugs were used 
to block specific degradation pathways, as described previously40, 41: Leupeptin (Alfa Aesar, 100 µM, broad pro-
tease inhibitor); MG132 (Sigma, 25 µM, blocks 26S proteasome); Bafilomycin A1 (InvivoGen, 400 nM, inhibits 
vacuolar-type H+ ATPases, preventing vesicle acidification and lysosomal function).
Statistical analysis. GraphPad Prism was used for statistical analysis. One way ANOVA and Dunnett’s mul-
tiple comparisons test was used for all analyses, except where indicated (for single comparisons), where Student’s 
2-tailed t-test was used. n.s. = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
Numbers given in parentheses in the text are in the form (mean ± SEM, n).
Accession numbers. SNP datasets and Illumina HT12v4 expression array datasets for previously unpub-
lished iPSC lines have been deposited in GEO, under Accession number GSE89886.
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